CURRENT ISSUES OF RESISTANT TUBERCULOSIS AND SMOKING (review)
PDF

Keywords

tuberculosis, smoking, Mycobacterium tuberculosis, multidrug-resistant tuberculosis, extensively drug-resistant tuberculosis

Abstract

Tuberculosis and smoking are among the most pressing issues in the modern health care system in the world. Tuberculosis patients who smoke are confirmed to have reduced the effectiveness of anti-tuberculosis therapy, unsatisfactory prognosis of a specific disease, higher risk of treatment failure and mortality from this disease. Diseases such as HIV and alcoholism increase ineffective treatment in tobacco smokers. In addition, smoking leads to increased virulence of the causative agent of tuberculosis - Mycobacterium tuberculosis.

https://doi.org/10.35339/ic.9.1.24-30
PDF

References

World Health Organisation. Global tuberculosis report, 2020. Geneva, Switzerland: WHO; 2021. Available at: https://www.who.int/teams/global-tuberculosis-programme/data

Feshchenko YI. Up-to-date tendencies in tuberculosis research. Ukr. Pulmonol. J. 2019;1:8–24.

Types of drug-resistant TB. Global Tuberculosis Programme. Geneva, Switzerland: WHO; 2019. Available at: https://www.who.int/teams/global-tuberculosis-programme/diagnosis-treatment/treatment-of-drug-resistant-tb/types-of-tb-drug-resistance

Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). The WHO newsletter. Geneva, Switzerland: WHO; 16 January 2018. Available at: https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug- resistant-tuberculosis-(mdr-tb)

WHO announces updated definitions of extensively drug-resistant tuberculosis. The WHO newsletter. Geneva, Switzerland: WHO; 27 January 2021. Available at: https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis

Analytical and statistical reference book for 2020. Public Health Center of the Ministry of Health of Ukraine. Center for Medical Statistics of the Ministry of Health of Ukraine. Kyiv: Ministry of Health of Ukraine; 2021. 92 p.

Мelnyk VМ, Мatusevych VG., Novozhylova IА, Veselovskyi LV, Bushura IV, Prykhodko АN. Situation with the relapses of tuberculosis in different countries of the world. Ukr. Pulmonol. J. 2021;1:5–10.

World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019. Available at: https://apps.who.int/iris/handle/10665/311389.

First global consultation on the role of e/mHealth in TB and tobacco control. The WHO newsletter. Geneva, Switzerland: WHO; 11 Jun 2015. Available at: https://www.who.int/news/item/11-06-2015-first-global-consultation-on-the-role-of-e-mhealth-in-tb-and-tobacco-control.

WHO Global Report: Mortality attributable to tobacco. Geneva: World Health Organization; 2012. Available at: https://www.who.int/publications/i/item/9789241564434 [Accessed 7 Jun 2021].

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990‒2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223‒49. DOI: 10.1016/S0140-6736(20)30752-2.

Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. To-bacco Control. 1994;3(3):242–247.

Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018;44(2):145‒52. DOI: 10.1590/s1806-37562017000000443.

WHO global report on trends in prevalence of tobacco use 2000–2025. Geneva: World Health Organization; 2021. Available at: https://www.who.int/publications/i/item/9789240039322.

GYTS (Global Youth Tobacco Survey) Fact Sheet, Ukraine, 2018. Available at: https://moz.gov.ua/uploads/ 1/8546- ukraine_gyts_2017_factsheet_ages_13_15_final_4_2_2018_508tagged_1.pdf

Global adult survey on tobacco use in Ukraine. Kyiv: Ministry of Health of Ukraine; 2017. 243 p. Available at: https://moz.gov.ua/uploads/1/8545-full_report_gats_ukraine_2017_ukr.pdf

Loddenkemper R, Brönnecke M, Castell S, Diel R. Tuberkulose und Rauchen [Tuberculosis and Tobacco Smoking]. Pneumologie. 2016;70(1):17‒22. DOI: 10.1055/s-0041-109601. [In German].

Underner M, Perriot J, Peiffer G, Meurice JC, Dautzenberg B. Tabagisme et observance du traitement an-tituberculeux [Smoking and adherence to anti-tuberculosis treatment]. Rev Mal Respir. 2016;33(2):128‒44. DOI: 10.1016/j.rmr.2015.08.005. [In French].

van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27-33. DOI: 10.1183/09031936.00072909.

North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol. 2004;22:599‒623. DOI: 10.1146/annurev.immunol.22.012703.104635.

Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445‒54. DOI: 10.1056/NEJMra0804752.

Shaler CR, Horvath CN, McCormick S, Jeyanathan M, Khera A, Zganiacz A, Kasinska J, Stampfli MR, Xing Z. Continuous and discontinuous cigarette smoke exposure differentially affects protective Th1 immunity against pul-monary tuberculosis. PLoS One. 2013;8(3):e59185. DOI: 10.1371/journal.pone.0059185.

Miramontes CV, Rodríguez-Carlos A, Marin-Luévano SP, Trejo Martínez LA, de Haro Acosta J, Enciso-Moreno JA, Rivas-Santiago B. Nicotine promotes the intracellular growth of Mycobacterium tuberculosis in epithelial cells. Tuberculosis (Edinb). 2021;127:102026. DOI: 10.1016/j.tube.2020.102026.

Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Mui-o A, Lopez MV. Tuberculosis and airflow ob-struction evidence from the PLATINO study in Latin America. Eur Respir J. 2007;30(6):1180–5. DOI: 10.1183/09031936. 00083507.

Slama K, Chiang CY, Enarson DA, Hassmiller K, Fanning A, Gupta P. Tobacco and tuberculosis a qualita-tive systematic review and meta-analysis. Int J Tuberc Lung Dis. 2007;11(10):1049–61.

Du Preez K, Mandalakas AM, Kirchner HL, Grewal HM, Schaaf HS, van Wyk SS, Hesseling AC. Environ-mental tobacco smoke exposure increases Mycobacterium tuberculosis infection risk in children. Int J Tuberc Lung Dis. 2011;15(11):1490–6. DOI: 10.5588/ijtld.10.0759.

Altet MN, Alcaide J, Plans P, Taberner JL, Saltó E, Folguera LI. Passive smoking and risk of pulmonary tu-berculosis in children immediately following infection A case control study. Tuber Lung Dis. 1996;77(6):537–44. DOI: 10.1016/S0962-8479(96)90052-0.

Reimann M, Schaub D, Kalsdorf B, Runge C, Carballo PS, Terhalle E, et al. Cigarette smoking and culture conversion in patients with susceptible and M/XDR-TB. Int J Tuberc Lung Dis. 2019;23(1):93‒8. DOI: 10.5588/ijtld.18.0354.

Wang EY, Arrazola RA, Mathema B, Ahluwalia IB, Mase SR. The impact of smoking on tuberculosis treat-ment outcomes: a meta-analysis. Int J Tuberc Lung Dis. 2020;24(2):170‒5. DOI: 10.5588/ijtld.19.0002.

Wang MG, Huang WW, Wang Y, Zhang YX, Zhang MM, Wu SQ, Sandford AJ, He JQ. Association between tobacco smoking and drug-resistant tuberculosis. Infect Drug Resist. 2018;11:873-887. DOI: 10.2147/IDR.S164596.

Balian DR, Davtyan K, Balian A, Grigoryan A, Hayrapetyan A, Davtyan H. Tuberculosis treatment and Smoking, Armenia, 2014‒2016. J Clin Tuberc Other Mycobact Dis. 2017;8:1‒5. DOI: 10.1016/j.jctube.2017.04.001.

Aguilar JP, Arriaga MB, Rodas MN, Martins Netto E. Smoking and pulmonary tuberculosis treatment failure: a case-control study. J Bras Pneumol. 2019;45(2):e20180359. DOI: 10.1590/1806-3713/e20180359.

Thomas BE, Thiruvengadam K, Rani S, Kadam D, Ovung S, Sivakumar S, et al.; CTRIUMPH-RePORT In-dia Study. Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored. PLoS One. 2019;14(7):e0220507. DOI: 10.1371/journal.pone.0220507. PMID: 31365583.

Khan AH, Israr M, Khan A, Aftab RA, Khan TM. Smoking on treatment outcomes among tuberculosis pa-tients. Am J Med Sci. 2015;349(6):505–9. DOI: 10.1097/MAJ.0000000000000473.

d’Arc Lyra Batista J, de Fátima Pessoa Militão de Albuquerque M, de Alencar Ximenes RA, Rodrigues LC. Smoking increases the risk of relapse after successful tuberculosis treatment. Int J Epidemiol. 2008;37(4):841–51. DOI: 10.1093/ije/dyn113.

Cherkaoui I, Sabouni R, Ghali I, Kizub D, Billioux AC, Bennani K. Treatment default amongst patients with tuberculosis in urban Morocco predicting and explaining default and post-default sputum smear and drug susceptibility results. PLoS One. 2014;9(4):e93574. DOI: 10.1371/journal.pone.0093574.

Zhang H, Xin H, Li X, Li H, Li M, Lu W. A dose-response relationship of smoking with tuberculosis infec-tion A cross-sectional study among 21008 rural residents in China. PLoS One. 2017;12(4):e0175183. DOI: 10.1371/ journal.pone.0175183.

Altet N, Latorre I, Jiménez-Fuentes MÁ, Maldonado J, Molina I, González-Díaz Y. Assessment of the influ-ence of direct tobacco smoke on infection and active TB management. PLoS One. 2017;12(8):e0182998. DOI: 10.1371/journal.pone.0182998.

Eastment MC, McClintock AH, McKinney CM, Narita M, Molnar A. Factors That Influence Treatment Completion for Latent Tuberculosis Infection. J Am Board Fam Med. 2017;30(4):520–7. DOI: 10.3122/jabfm.2017.04.170070.

de Vargas KR, Freitas AA, Azeredo ACV, Silva DR. Smoking prevalence and effects on treatment outcomes in patients with tuberculosis. Rev Assoc Med Bras (1992). 2021;67(3):406‒10. DOI: 10.1590/1806-9282.20200825.

Siddiqi K, Keding A, Marshall AM, Dogar O, Li J, Huque R, Fatima R, et al. Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. Thorax. 2022;77(1):74‒8. DOI: 10.1136/thoraxjnl-2020-215926.

Rodríguez-Fernández P, Gómez AC, Gibert I, Prat-Aymerich C, Domínguez J. Effects of cigarette smoke on the administration of isoniazid and rifampicin to macrophages infected with Mycobacterium tuberculosis. Exp Lung Res. 2021;47(2):87‒97. DOI: 10.1080/01902148.2020.1854371.

Hong S, Mok Y, Jeon C, Jee SH, Samet JM. Tuberculosis, smoking and risk for lung cancer incidence and mortality. Int J Cancer. 2016;139(11):2447‒55. DOI: 10.1002/ijc.30384.

Chiang YC, Lin YM, Lee JA, Lee CN, Chen HY. Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy. Int J Infect Dis. 2012;16(2):e130‒5. DOI: 10.1016/j.ijid.2011.10.007. PMID: 22185828.

Bonacci RA, Cruz-Hervert LP, García-García L, Reynales-Shigematsu LM, Ferreyra-Reyes L, Bobadilla-del-Valle M, et al. Impact of cigarette smoking on rates and clinical prognosis of pulmonary tuberculosis in Southern Mex-ico. J Infect. 2013;66(4):303‒12. DOI: 10.1016/j.jinf.2012.09.005. PMID: 22982014.

Wen CP, Chan TC, Chan HT, Tsai MK, Cheng TY, Tsai SP. The reduction of tuberculosis risks by smoking cessation. BMC Infect Dis. 2010;10:156. DOI: 10.1186/1471-2334-10-156.

Mrigpuri P, Gupta A, Jha R, Singla P, Singla R. Tobacco use, tuberculosis and COVID-19: A lethal triad. Indian J Tuberc. 2021;68S:S86‒8. DOI: 10.1016/j.ijtb.2021.08.010.

Kim DJ, Oh JY, Rhee CK, Park SJ, Shim JJ, Cho JY. Metabolic Fingerprinting Uncovers the Distinction Between the Phenotypes of Tuberculosis Associated COPD and Smoking-Induced COPD. Front Med (Lausanne). 2021;8:619077. DOI: 10.3389/fmed.2021.619077.

Willemse D, Moodley C, Mehra S, Kaushal D. Transcriptional Response of Mycobacterium tuberculosis to Cigarette Smoke Condensate. Front Microbiol. 2021;12:744800. DOI: 10.3389/fmicb.2021.744800.

McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):292‒302. DOI: 10.1093/jac/dkt364. PMID: 24072169.

Cholo MC, Rasehlo SSM, Venter E, Venter C, Anderson R. Effects of Cigarette Smoke Condensate on Growth and Biofilm Formation by Mycobacterium tuberculosis. Biomed Res Int. 2020;2020:8237402. DOI: 10.1155/2020/ 8237402. PMID: 32923486.

Miramontes CV, Rodríguez-Carlos A, Marin-Luévano SP, Trejo Martínez LA, de Haro Acosta J, Enciso-Moreno JA, Rivas-Santiago B. Nicotine promotes the intracellular growth of Mycobacterium tuberculosis in epithelial cells. Tuberculosis (Edinb). 2021;127:102026. DOI: 10.1016/j.tube.2020.102026. PMID: 33262029.

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.